Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

Cancer and Metastasis Reviews

Volumn 34, Issue 3, 2015, Pages 381-400

  Jimenez Fonseca P ^a   Carmona Bayonas, A ^b   Martin Perez E ^c   Crespo, G ^d   Serrano, R ^e   Llanos, M ^f   Villabona, C ^g   Garcia Carbonero R ^h   Aller, J ⁱ   Capdevila, J ^j   Grande, E ^k  

^a Department of Hematology   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Chemotherapy; Gastroenteropancreatic neuroendocrine tumors (GEP NETs); Health related quality of life (HRQoL); Locoregional therapy; Peptide receptor radionuclide therapy (PRRT); Quality of life (QoL); Questionnaires; Somatostatin analogs (SSA); Surgery; Targeted therapy

Indexed keywords

EVEROLIMUS; SOMATOSTATIN DERIVATIVE; SUNITINIB;

ABLATION THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HEALTH STATUS; HUMAN; MENTAL HEALTH; MOLECULARLY TARGETED THERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; COMPLICATION; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PSYCHOLOGY; STOMACH NEOPLASMS;

HUMANS; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; QUALITY OF LIFE; STOMACH NEOPLASMS;

EID: 84942193030     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9573-1     Document Type: Article

References (149)

1. Yao, J. C., Hassan, M., Phan, A., et al. (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. Journal of Clinical Oncology, 26(18), 3063–3072.
2. Beaumont, J. L., Cella, D., Phan, A. T., Choi, S., Liu, Z., & Yao, J. C. (2012). Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas, 41(3), 461–466.
3. Larsson, G., Sjoden, P. O., Oberg, K., Eriksson, B., & von Essen, L. (2001). Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica, 40(7), 825–831.
4. US Department of Health and Human Services. (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4, 79.
5. Redeker, N. S., Lev, E. L., & Ruggiero, J. (2000). Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Scholarly Inquiry for Nursing Practice, 14(4), 275–290. discussion 291–8.
6. Cella, D. (1998). Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology, 25(3 Suppl 7), 43–46.
7. Coates, A., Gebski, V., Bishop, J. F., et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New England Journal of Medicine, 317(24), 1490–1495.
8. Ganz, P. A., Lee, J. J., & Siau, J. (1991). Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 67(12), 3131–3135.
9. Haugland, T., Vatn, M. H., Veenstra, M., Wahl, A. K., & Natvig, G. K. (2009). Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Quality of Life Research, 18(6), 719–726.
10. Claringbold, P. G., Brayshaw, P. A., Price, R. A., & Turner, J. H. (2011). Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 38(2), 302–311.
11. Raymond, E., Dahan, L., Raoul, J. L., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501–513.
12. Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.
13. Teunissen, J. J., Kwekkeboom, D. J., & Krenning, E. P. (2004). Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Clinical Oncology, 22(13), 2724–2729.
14. Kalinowski, M., Dressler, M., Konig, A., et al. (2009). Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion, 79(3), 137–142.
15. Frilling, A., Weber, F., Saner, F., et al. (2006). Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 140(6), 967–968.
16. Bushnell, D. L., Jr., O’Dorisio, T. M., O’Dorisio, M. S., et al. (2010). 90Y-edotreotide for metastatic carcinoid refractory to octreotide. Journal of Clinical Oncology, 28(10), 1652–1659.
17. Zuetenhorst, J. M., Valdes Olmos, R. A., Muller, M., Hoefnagel, C. A., & Taal, B. G. (2004). Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocrine-Related Cancer, 11(3), 553–561.
18. Bajetta, E., Procopio, G., Catena, L., et al. (2006). Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer, 107(10), 2474–2481.
19. Ruszniewski, P., Ish-Shalom, S., Wymenga, M., et al. (2004). Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology, 80(4), 244–251.
20. Cwikla, J. B., Sankowski, A., Seklecka, N., et al. (2010). Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology, 21(4), 787–794.
21. Martin-Richard, M., Massuti, B., Pineda, E., et al. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer, 13(1), 427.
22. O’Toole, D., Ducreux, M., Bommelaer, G., et al. (2000). Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer, 88(4), 770–776.
23. Kulke, M. H., Lenz, H. J., Meropol, N. J., et al. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26(20), 3403–3410.
24. Kvols, L. K., Oberg, K. E., O’Dorisio, T. M., et al. (2012). Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer, 19(5), 657–666.
25. Jacobsen, M. B., & Hanssen, L. E. (1995). Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. Journal of Internal Medicine, 237(3), 269–275.
26. Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., & Riva, P. (2002). In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine, 32(2), 148–155.
27. Waldherr, C., Pless, M., Maecke, H. R., et al. (2002). Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine, 43(5), 610–616.
28. Forrer, F., Waldherr, C., Maecke, H. R., & Mueller-Brand, J. (2006). Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Research, 26(1B), 703–707.
29. Valkema, R., Pauwels, S., Kvols, L. K., et al. (2006). Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine, 36(2), 147–156.
30. Bushnell, D., O’Dorisio, T., Menda, Y., et al. (2003). Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 44(10), 1556–1560.
31. Muros, M. A., Varsavsky, M., Iglesias Rozas, P., et al. (2009). Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clinical and Translational Oncology, 11(1), 48–53.
32. Bodei, L., Cremonesi, M., Grana, C. M., et al. (2011). Peptide receptor radionuclide therapy with 177-Lu-DOTATATE: the IEO phase I–II study. European Journal of Nuclear Medicine and Molecular Imaging, 38(12), 2125–2135.
33. Khan, S., Krenning, E. P., van Essen, M., Kam, B. L., Teunissen, J. J., & Kwekkeboom, D. J. (2011). Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Nuclear Medicine, 52(9), 1361–1368.
34. Arnold, R., Rinke, A., Klose, K. J., et al. (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology, 3(8), 761–771.
35. Gyokeres, T., Pulgar, S., Singh, N., Passos, V. Q., & Kelemen, P. (2012). Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors. ASCO Meeting Abstract, 30(4_suppl), 362.
36. Wymenga, A. N., Eriksson, B., Salmela, P. I., et al. (1999). Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology, 17(4), 1111.
37. Caplin, M. E., Pavel, M., Cwikła, J. B., et al. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine, 371(3), 224–233.
38. Pavel, M., Unger, N., Borbath, I., et al. (2014). Safety and quality-of-life (QOL) assessments in the open-label, multicenter, phase 3b, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET). Pancreas, 43(3), 500–501.
39. Delpassand, E. S., Samarghandi, A., Zamanian, S., et al. (2014). Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas, 43(4), 518–525.
40. Frojd, C., Larsson, G., Lampic, C., & von Essen, L. (2007). Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health and Quality of Life Outcomes, 5, 18.
41. Larsson, G., von Essen, L., & Sjoden, P. O. (1999). Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncologica, 38(4), 481–490.
42. Berglund, G., Liden, A., Hansson, M. G., Oberg, K., Sjoden, P. O., & Nordin, K. (2003). Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). Familial Cancer, 2(1), 27–33.
43. Larsson, G., Haglund, K., & Von Essen, L. (2003). Distress, quality of life and strategies to “keep a good mood” in patients with carcinoid tumours: patient and staff perceptions. European Journal of Cancer Care, 12(1), 46–57.
44. Von Essen, L., Larsson, G., Oberg, K., & Sjoden, P. O. (2002). “Satisfaction with care”: associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. European Journal of Cancer Care, 11(2), 91–99.
45. Pezzilli, R., Campana, D., Morselli-Labate, A. M., Fabbri, M. C., Brocchi, E., & Tomassetti, P. (2009). Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. World Journal of Gastroenterology, 15(40), 5067–5073.
46. Van der Horst-Schrivers, A. N., van Ieperen, E., Wymenga, A. N., et al. (2009). Sexual function in patients with metastatic midgut carcinoid tumours. Neuroendocrinology, 89(2), 231–236.
47. You, Y. N., Thompson, G. B., Young, W. F., Jr., et al. (2007). Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery, 142(6), 829–836. discussion 836.e1.
48. Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G. (2009). Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology, 89(3), 296–301.
49. Davies, A. H., Larsson, G., Ardill, J., et al. (2006). Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 42(4), 477–484.
50. Vinik, E., Carlton, C. A., Silva, M. P., & Vinik, A. I. (2009). Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas, 38(3), e87–e95.
51. Yadegarfar, G., Friend, L., Jones, L., et al. (2013). Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. British Journal of Cancer, 108(2), 301–310.
52. Vinik, E., Silva, M. P., & Vinik, A. I. (2011). Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America, 40(1), 97–109.
53. Vinik, A., Bang, Y., Raoul, J., et al. (2010). Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. ASCO Meeting Abstract, 28(15_suppl), 4003.
54. Haugland, T., Veenstra, M., Vatn, M. H., & Wahl, A. K. (2013). Improvement in stress, general self-efficacy, and health related quality of life following patient education for patients with neuroendocrine tumors: a pilot study. Nursing Research Practice, 2013, 695820.
55. Larsson, G., von Essen, L., & Sjoden, P. O. (1998). Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions. Cancer Nursing, 21(6), 411–420.
56. Larsson, G., Sjoden, P. O., Oberg, K., & von Essen, L. (1999). Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Annals of Oncology, 10(11), 1321–1327.
57. Ramage, J. K., Davies, A. H., & Group EQ of L. (2003). Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocrine-Related Cancer, 10(4), 483–486.
58. Frojd, C., Lampic, C., Larsson, G., & von Essen, L. (2009). Is satisfaction with doctors’ care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report. Scandinavian Journal of Caring Sciences, 23(1), 107–116.
59. Kulke, M.H., O’Dorisio, T., Yang Qi, M., et al. (2015). Patient-reported symptom experiences following participation in a study of telotristat etiprate for patients with carcinoid tumor and octreotide-refractory diarrhea. Available at: http://www.nanets.net/nanets_cd/2013/pdfs/C13-kulkeabstract2.pdf.Accessed 20 June 2015.
60. Cheung, Y. B., Goh, C., Thumboo, J., Khoo, K. S., & Wee, J. (2005). Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. Journal of Clinical Oncology, 23(22), 4936–4944.
61. Kemmler, G., Holzner, B., Kopp, M., et al. (1999). Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer quality of life questionnaire-C30. Journal of Clinical Oncology, 17(9), 2932–2940.
62. Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.
63. Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual. Brussels: European Organisation for Research and Treatment of Cancer.
64. Bredart, A., Bottomley, A., Blazeby, J. M., et al. (2005). An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). European Journal of Cancer, 41(14), 2120–2131.
65. Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364.
66. Groenvold, M., Klee, M. C., Sprangers, M. A., & Aaronson, N. K. (1997). Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. Journal of Clinical Epidemiology, 50(4), 441–450.
67. Ringdal, G. I., & Ringdal, K. (1993). Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnoses. Quality of Life Research, 2(2), 129–140.
68. McLachlan, S. A., Devins, G. M., & Goodwin, P. J. (1999). Factor analysis of the psychosocial items of the EORTC QLQ-C30 in metastatic breast cancer patients participating in a psychosocial intervention study. Quality of Life Research, 8(4), 311–317.
69. Kaasa, S., Bjordal, K., Aaronson, N., et al. (1995). The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. European Journal of Cancer, 31A(13–14), 2260–2263.
70. Arraras, J. I., Arias, F., Tejedor, M., et al. (2002). The EORTC QLQ-C30 (version 3.0) quality of life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology, 11(3), 249–256.
71. Bjordal, K., de Graeff, A., Fayers, P. M., et al. (2000). A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. European Journal of Cancer, 36(14), 1796–1807.
72. Whistance, R. N., Conroy, T., Chie, W., et al. (2009). Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. European Journal of Cancer, 45(17), 3017–3026.
73. Fayers, P., Aaronson, N., Bjordal, K., et al. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European Organisation for Research and Treatment of Cancer.
74. Kulke, M. H., Stuart, K., Enzinger, P. C., et al. (2006). Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology, 24(3), 401–406.
75. Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118(8), 622–629.
76. Smith, K. W., Avis, N. E., & Assmann, S. F. (1999). Distinguishing between quality of life and health status in quality of life research: a meta-analysis. Quality of Life Research, 8(5), 447–459.
77. Covinsky, K. E., Wu, A. W., Landefeld, C. S., et al. (1999). Health status versus quality of life in older patients: does the distinction matter? American Journal of Medicine, 106(4), 435–440.
78. Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.
79. Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.
80. Cella, D., Beaumont, J. L., Liu, Z., Phan, A. T., Choi, S., & Yao, J. C. (2010). Neuroendocrine tumor disease state and PROMIS health-related quality of life scores. ASCO Meeting Abstract, 28(15_suppl), 6118.
81. Bucquet, D., Condon, S., & Ritchie, K. (1990). The French version of the Nottingham health profile. A comparison of items weights with those of the source version. Social Science and Medicine, 30(7), 829–835.
82. Larsson, G., & Janson, E. T. (2008). Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life. European Journal of Cancer Care, 17(2), 200–204.
83. Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.
84. Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63–74.
85. Schell, S. R., Camp, E. R., Caridi, J. G., & Hawkins, I. F., Jr. (2002). Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. Journal of Gastrointestinal Surgery, 6(5), 664–670.
86. Boudreaux, J. P., Putty, B., Frey, D. J., et al. (2005). Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Annals of Surgery, 241(6), 839–845.
87. Gulec, S. A., Mountcastle, T. S., Frey, D., et al. (2002). Cytoreductive surgery in patients with advanced-stage carcinoid tumors. American Surgeon, 68(8), 667–671.
88. Knox, C. D., Feurer, I. D., Wise, P. E., et al. (2004). Survival and functional quality of life after resection for hepatic carcinoid metastasis. Journal of Gastrointestinal Surgery, 8(6), 653–659.
89. Oken, M. M., Creech, R. H., Tormey, D. C., et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology group. American Journal of Clinical Oncology, 5(6), 649–655.
90. Karnofsky, D. A., & Burchenal, J. H. (1949). The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press.
91. Blazeby, J. M., Fayers, P., Conroy, T., et al. (2009). Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. British Journal of Surgery, 96(3), 291–298.
92. Derogatis, L. R. (1986). The psychosocial adjustment to illness scale (PAIS). Journal of Psychosomatic Research, 30(1), 77–91.
93. Horowitz, M., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.
94. Scheier, M. F., Carver, C. S., & Bridges, M. W. (1994). Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. Journal of Personality and Social Psychology, 67(6), 1063–1078.
95. Vodermaier, A., Linden, W., & Siu, C. (2009). Screening for emotional distress in cancer patients: a systematic review of assessment instruments. Journal of the National Cancer Institute, 101(21), 1464–1488.
96. Hatton, M. Q., & Reed, N. S. (1997). Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience. Clinical Oncology (Royal College of Radiologists), 9(6), 385–389.
97. Khan, M. S., & Caplin, M. E. (2011). Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 18(Suppl 1), S53–S74.
98. Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003). Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgery, 197(1), 29–37.
99. Touzios, J. G., Kiely, J. M., Pitt, S. C., et al. (2005). Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery, 241(5), 775–776.
100. Ahmed, A., Turner, G., King, B., et al. (2009). Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocrine-Related Cancer, 16(3), 885–894.
101. Mayo, S. C., de Jong, M. C., Bloomston, M., et al. (2011). Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Annals of Surgical Oncology, 18(13), 3657–3665.
102. Meranze, S. G., Bream, P. R., & Grzeszczak, E. (2007). Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Presented as a poster at the society of interventional radiology (SIR) 32nd annual scientific meeting 2007; Abs 422. Journal of Vascular and Interventional Radiology, 18(1), S150–S151.
103. Osborne, D. A., Zervos, E. E., Strosberg, J., et al. (2006). Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Annals of Surgical Oncology, 13(4), 572–581.
104. Hung, J. S., Chang, M. C., Lee, P. H., & Tien, Y. W. (2007). Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World Journal of Surgery, 31(12), 2392–2397.
105. Saxena, A., Chua, T. C., Perera, M., Chu, F., & Morris, D. L. (2012). Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surgical Oncology, 21(3), e131–e141.
106. Drougas, J. G., Anthony, L. B., Blair, T. K., et al. (1998). Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery, 175(5), 408–412.
107. Loewe, C., Schindl, M., Cejna, M., Niederle, B., Lammer, J., & Thurnher, S. (2003). Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR American Journal of Roentgenology, 180(5), 1379–1384.
108. Diamandidou, E., Ajani, J. A., Yang, D. J., et al. (1998). Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. American Journal of Roentgenology, 170(2), 339–344.
109. Wessels, F. J., & Schell, S. R. (2001). Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. Journal of Surgical Research, 95(1), 8–12.
110. Maire, F., Lombard-Bohas, C., O’Toole, D., et al. (2012). Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology, 96(4), 294–300.
111. Rajekar, H., Bogammana, K., & Stubbs, R. S. (2011). Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. International Journal of Hepatology, 2011, 404916.
112. Chambers, A. J., Pasieka, J. L., Dixon, E., & Rorstad, O. (2008). The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery, 144(4), 643–645.
113. Karnofsky, D. A., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948). The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer, 1(4), 634–656.
114. Pavel, M., Baudin, E., Couvelard, A., et al. (2012). ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 95(2), 157–176.
115. Yang, T. X., Chua, T. C., & Morris, D. L. (2012). Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surgical Oncology, 21(4), 299–308.
116. Elias, D., Goere, D., Leroux, G., et al. (2009). Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. European Journal of Surgical Oncology, 35(10), 1092–1097.
117. Huang, Y.-Z., Zhou, S.-C., Zhou, H., & Tong, M. (2013). Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepato-Gastroenterology, 60(125), 1131–1135.
118. Akyildiz, H. Y., Mitchell, J., Milas, M., Siperstein, A., & Berber, E. (2010). Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery, 148(6), 1288–1293.
119. National Cancer Institute (2015). Common terminology criteria for adverse effects (CTCAE) v3.0. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed: 20 June 2015.
120. Krabbe, P. F., Peerenboom, L., Langenhoff, B. S., & Ruers, T. J. (2004). Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Quality of Life Research, 13(7), 1247–1253.
121. Fayers, P. M., & Sprangers, M. A. (2002). Understanding self-rated health. Lancet, 359(9302), 187–188.
122. Maton, P. N., Gardner, J. D., & Jensen, R. T. (1989). Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Digestive Diseases and Sciences, 34(3 Suppl), 28S–39S.
123. Oberg, K., Kvols, L., Caplin, M., et al. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15(6), 966–973.
124. Capdevila, J., Sevilla, I., Alonso, V., et al. (2015). Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 15, 495.
125. Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine, 326(8), 519–523.
126. Moertel, C. G., Kvols, L. K., O’Connell, M. J., & Rubin, J. (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68(2), 227–232.
127. Eriksson, B., Skogseid, B., Lundqvist, G., Wide, L., Wilander, E., & Oberg, K. (1990). Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer, 65(9), 1883–1890.
128. Ramanathan, R. K., Cnaan, A., Hahn, R. G., Carbone, P. P., & Haller, D. G. (2001). Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology, 12(8), 1139–1143.
129. Strosberg, J. R., Fine, R. L., Choi, J., et al. (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117(2), 268–275.
130. Fine, R. L., Gulati, A. P., Krantz, B. A., et al. (2013). Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemotheraphy and Pharmacology, 71(3), 663–670.
131. Lopez-Lopez, C., Jimenez, P., Crespo, G., et al. (2013). Temozolamide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting. ASCO Meeting Abstract, 31(15_suppl), e15169.
132. Maire, F., Hammel, P., Faivre, S., et al. (2009). Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology, 90(1), 67–72.
133. Ekeblad, S., Sundin, A., Janson, E. T., et al. (2007). Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research, 13(10), 2986–2991.
134. Chan, J. A., Stuart, K., Earle, C. C., et al. (2012). Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 30(24), 2963–2968.
135. Oberg, K., Casanovas, O., Castaño, J. P., et al. (2013). Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clinical Cancer Research, 19(11), 2842–2849.
136. Benavent, M., de Miguel, M. J., & Garcia-Carbonero, R. (2012). New targeted agents in gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 7(2), 99–106.
137. Missiaglia, E., Dalai, I., Barbi, S., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28(2), 245–255.
138. Pavel, M., Hainsworth, J. D., Baudin, E., Peeters, M., & Hobday, T. J. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs placebo + octreotide LAR in patients with neuroendocrine tumors (NET). Annals of Oncology, 21, viii–4.
139. Yao, J. C., Shah, M. H., Ito, T., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 514–523.
140. Yao, J. C., Hainsworth, J. D., Wolin, E. M., et al. (2012). Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E + O) or placebo (P + O) among patients with advanced neuroendocrine tumors (NET). ASCO Meeting Abstract, 30(4_suppl), 157.
141. Burris, H. A., 3rd, Lebrun, F., Rugo, H. S., et al. (2013). Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer, 119(10), 1908–1915.
142. Motzer, R. J., Escudier, B., Oudard, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372(9637), 449–456.
143. Strosberg, J. R., Lincy, J., Winkler, R. E., & Wolin, E. M. (2011). Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). ASCO Meeting Abstract, 29(15_suppl), 4009.
144. Phan, A. T. (2013). Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. Cancer Treatment Reviews, 39(1), 3–9.
145. Raymond, E., Hammel, P., Dreyer, C., et al. (2012). Sunitinib in pancreatic neuroendocrine tumors. Targeted Oncology, 7(2), 117–125.
146. Oberstein, P. E., & Saif, M. W. (2012). Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clinical Medicine Insights Oncology, 6, 41–51.
147. Grande, E., Capdevila, J., Castellano, D., et al. (2015). Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, pii: mdv252. [Epub ahead of print]
148. Jiao, Y., Shi, C., Edil, B. H., et al. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331(6021), 1199–1203.
149. Yao, J. C., Pavel, M., Phan, A. T., et al. (2011). Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism, 96(12), 3741–3749.